Previous 10 | Next 10 |
Provention Bio (NASDAQ:PRVB): Q2 GAAP EPS of -$0.46 beats by $0.06. Cash and cash equivalents and marketable securities of $176.4 million. Press Release For further details see: Provention Bio EPS beats by $0.06
Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update PR Newswire RED BANK, N.J. , Aug. 5, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-me...
It's been almost 18 months since I posted a comprehensive clinical overview of Provention Bio's main molecule teplizumab. I advised investors to avoid the stock due to an over-exuberance in potential for the At-Risk application of teplizumab. Shares have fallen ~60% since then, an...
Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021 PR Newswire RED BANK, N.J. , July 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-media...
Altimmune (ALT) stock sold off after the company announced its plan to scrap its COVID19 vaccine programs, and ALT is currently trading at an enterprise value of around US$120M. We believe ALT's NASH and obesity pipeline drives most of its value. The recent sell-off offers an attracti...
Gainers: [[NRXP]] +10.1%. [[PDD]] +6.6%. [[TLSA]] +6.3%. [[AFMD]] +4.4%. [[UXIN]] +3.8%.Losers: [[ACOR]] -3.8%. [[IPA]] -2.8%. [[SNCR]] -2.5%. [[PRVB]] -2.3%. [[INCY]] -3.3%. For further details see: NRXP, PDD, ACOR and IPA among after-hours movers
Sometimes the market overreacts to a negative development. Shares of Provention Bio (NASDAQ: PRVB) recently plunged after the FDA issued a Complete Response Letter for its diabetes drug teplizumab. In this Motley Fool Live video recorded on July 7 , Motley Fool contribu...
Teplizumab Awarded Innovation Passport in the United Kingdom (UK) for the Delay of Onset of Clinical Type 1 Diabetes in At-risk Individuals Designation is the first step in a new MHRA initiative to accelerate the development and access to innovative medicines in the UK post-Brex...
Shares of Provention Bio (NASDAQ: PRVB) , a clinical-stage biopharmaceutical company, were beaten down 25.2% as of 12:40 p.m. EDT on Tuesday. Investors are responding to a Complete Response Letter that the company received from the Food and Drug Administration instead of an approval...
Gainers: Orbsat (OSAT) +86%.BSQUARE (BSQR) +71%.PFSweb (PFSW) +36%.Advaxis (ADXS) +35%.Powerbridge Technologies (PBTS) +34%.Bridgeline Digital (BLIN) +31%.Sequential Brands Group (SQBG) +24%.GasLog Partners (GLOP) +24%.BioHiTech Global (BHTG) +20%.Data Storage (DTST) +19%.Losers: Pop Culture ...
News, Short Squeeze, Breakout and More Instantly...
Provention Bio, Inc. (NASDAQ: PRVB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 3.14% on the day to $24.99. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and comme...
2023-04-06 11:29:16 ET What Are Penny Stocks? The market for penny stocks has continued growing over the last few years. But what are these stocks in the first place? The general definition of penny stocks includes shares of companies trading below $5. Making money with penny st...
NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale t...